Skip to content
Head to head

Haleon vs Takeda Pharmaceutical

Side-by-side on the measures that matter, with a plain-English read. Full detail: HLN · TAK

Updated 8 minutes ago

1-year performance, rebased to 100

HLN -4.4%TAK +56.6%
Takeda Pharmaceutical edges it on the scoreable measures. Takeda Pharmaceutical has the highest Quant Rating (90); Takeda Pharmaceutical has done best over the past year (+57%).
HLNTAK
Snapshot
SectorDrug Manufacturers - Specialty & Generic--
Last price9.0721.77
Change today+0.22%+1.68%
1-year return-3.6%+57.5%
Market cap$39.76B$69.76B
52-week range8.38 – 11.0613.92 – 22.07
Valuation
P/E (TTM)19.14311.00
P/E percentile, own 5-yr range15th100th
P/B1.851.50
Dividend yield2.09%1.44%
Profitability & growth
EPS (TTM)0.48-0.30
Net profit (TTM)$2.12B$-970.94M
Revenue (TTM)$11.23B$4.69T
Provider revenue period date2024-12-302026-09-29
Revenue growth (YoY)-0.3%+6.7%
Gross margin65.0%65.8%
Operating margin21.4%14.3%
Net margin14.6%0.9%
Free cash flow (TTM)--$433.95B
Provider cash-flow period date--2026-09-29
Ownership & sentiment
Institutional ownership95.3%51.3%
Insider activity (12mo)0 buy / 2 sell19 buy / 31 sell
Short interest (% of float)0.3%0.1%
Analyst consensus100% buy (1)100% buy (1)
Analyst price target$11 (+21%)$50 (+132%)
StockVane view
StockVane Quant RatingD (37)C (90)
Company
Employees24,53547,029
Founded20211781

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.